Clinical trials
HSCT clinical trials
Below are recruiting hsct clinical trials, each written for real people, not researchers. We’re tracking 160 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06860269RecruitingPhase 2/Phase 3
New immune therapy and stem cell transplant for acute lymphoblastic leukemia
This study tests adding new immunotherapy drugs and possibly a stem cell transplant to the first treatment for adults with acute lymphoblastic leukemia (ALL). The goal is to see if these approaches help people live longer without the cancer coming back.
ParisAges 18–65 - NCT06650553Recruiting
Cord blood stem cell transplant for aplastic anemia
This study tests whether adding umbilical cord blood to a stem cell transplant from a half-matched donor can improve outcomes for people with severe aplastic anemia or related bone marrow failure diseases.
Taiyuan, ShanxiAges 6–75 - NCT03314974RecruitingPhase 2
Stem cell transplant study for blood cancers
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
Minneapolis, MinnesotaAges Up to 60 years - NCT07823036RecruitingPhase 1/Phase 2
MRI scans of lungs after stem cell transplant
This study uses MRI scans to look at the lungs in people who have had a stem cell transplant (HSCT). It will help doctors understand and detect early lung problems, so they can act sooner.
Cincinnati, OhioAges 3 years+ - NCT06471946RecruitingPhase 1/Phase 2
Stem cell transplant for older patients with high-risk MDS
This trial tests a special conditioning regimen (VA) before a stem cell transplant for older patients with higher-risk myelodysplastic syndrome (MDS). It aims to make the transplant safer and more effective for this group.
Beijing, Beijing MunicipalityAges 70 years+ - NCT06625372Recruiting
Comparing two IV nutrition options for children after stem cell transplant
This study compares two types of IV nutrition (Intralipid and SMOF Lipid) for children undergoing stem cell transplants for leukemia. It aims to find which option is better for helping them recover.
TehranAges 2–18 - NCT07688759Recruiting
Immune response measurement for first CMV after transplant
This trial is for adults who have had a stem cell transplant and now have their first CMV infection. It tests a way to measure your immune response to CMV, which may help doctors decide the best treatment for you.
Suzhou, JiangsuAges 18 years+ - NCT07680933RecruitingPhase 2
Orelabrutinib plus chemo for newly diagnosed DLBCL
This trial tests if adding orelabrutinib (a targeted pill) to standard chemotherapy, with or without a stem cell transplant, works better for people with a new diagnosis of diffuse large B-cell lymphoma. It may help patients who have a higher risk of the lymphoma coming back.
Xuzhou, JiangsuAges 18–80 - NCT06715046Recruiting
Blood DNA test after stem cell transplant
This study checks if looking at DNA in your blood can help doctors see how well your stem cell transplant is working and catch any problems early. It is for people with blood cancers getting a transplant from a donor.
Milan, MilanAges 18 years+ - NCT07588360Recruiting
Stem cell transplant for acute myeloid leukemia or myelodysplastic syndrome
This trial tests a type of stem cell transplant (using cells from a partially matched donor and umbilical cord blood) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to help patients whose disease is high-risk, has returned after treatment, or hasn't responded well to chemotherapy.
Fuzhou, FujianAges 14–60 - NCT06769191RecruitingEarly Phase 1
CD7 car-t, stem cell transplant, and kidney transplant for SIOD
This trial tests a sequence of treatments for SIOD (a genetic condition causing immune and kidney problems). First, you receive CD7 car-t cells, then a stem cell transplant from a family donor, followed by a kidney transplant from the same donor. The goal is to see if this approach is safe and can help your body accept the new kidney.
Hangzhou, ZhejiangAges Any age - NCT06787560RecruitingEarly Phase 1
CAR-T cells and stem cell transplant for blood diseases
This trial tests a new approach for people with non-cancerous blood and immune system diseases. It uses your own engineered immune cells (CAR-T cells) to prepare your body for a stem cell transplant from a relative.
Hangzhou, ZhejiangAges Any age - NCT07321626RecruitingPhase 1
Romiplostim for platelet recovery after stem cell transplant
This trial tests if romiplostim, a drug that helps the body make platelets, can speed up platelet recovery after a special type of stem cell transplant from a half-matched donor. It may help reduce bleeding risk during the recovery period.
HangzhouAges 18 years+ - NCT07284641RecruitingPhase 2
Stem cell transplant for immune disorders
This trial tests a stem cell transplant to treat common variable immunodeficiency (CVID) and other immune problems. It aims to replace a faulty immune system with a healthy one from a donor.
Pittsburgh, PennsylvaniaAges 5–40 - NCT07253129Recruiting
Stem cell transplant study for T-cell lymphoma patients with partial response
This study compares two types of stem cell transplants (from a donor or your own cells) for people with certain T-cell lymphomas who had only a partial response to first chemotherapy. It aims to see which approach may work better.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06707493RecruitingPhase 2
Ivosidenib after stem cell transplant for IDH1-mutated AML
This study tests whether a daily pill called ivosidenib can help prevent AML from coming back after a stem cell transplant. It is for people whose AML has a specific IDH1 gene change and who are planning to have a transplant.
Atlanta, GeorgiaAges 18–75 - NCT06507514RecruitingPhase 1
Blinatumomab with stem cell transplant for B-ALL
This trial tests a treatment plan that uses blinatumomab (a drug that helps your immune system attack leukemia cells) combined with your own stem cell transplant. It is for people with B-ALL who cannot or choose not to have a transplant from another person.
Suzhou, JiangsuAges 15–65 - NCT06326008RecruitingPhase 1
Donor immune cell therapy for leukemia that returned after treatment
This trial tests a two-step approach using donor immune cells to treat children with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. First, a donor's CD19-targeted cells are given to bridge to a stem cell transplant, followed by CD22-targeted cells to prevent relapse.
Beijing, Beijing MunicipalityAges 1–18 - NCT06119256RecruitingPhase 1
TCR-T cells for EBV after stem cell transplant
This trial tests a new treatment using specially trained immune cells (TCR-T cells) to fight Epstein-Barr virus (EBV) infections that can occur after a stem cell transplant for blood cancer. It may help control the virus and prevent complications.
Beijing, Beijing MunicipalityAges 14–75 - NCT04098445Recruiting
Study of lung injury in children after stem cell transplant
This study follows children and teens who get a stem cell transplant to learn how lung problems develop over time. Your participation could help doctors better predict, prevent, and manage lung injury after transplant.
San Francisco, CaliforniaAges Up to 24 years - NCT03793517RecruitingPhase 2/Phase 3
Decitabine plus chemotherapy before stem cell transplant for high-risk leukemia
This trial studies whether adding decitabine plus chemotherapy before a stem cell transplant can better control “minimal residual disease” (very small amounts of leukemia left behind) in certain high-risk acute leukemia types. It may help reduce the chance of the leukemia coming back after transplant.
Beijing, Beijing MunicipalityAges 18–55 - NCT04179929Recruiting
Study for adults with Ph-negative ALL
This trial looks at how to treat a type of leukemia called Ph-negative ALL in adults. It may help people by testing a treatment approach specifically for this leukemia subtype.
Badalona, BarcelonaAges 18–60 - NCT04689750Recruiting
Testing outcomes after donor CHIP in stem cell transplant
This study looks at how a genetic risk factor in a stem cell donor (called CHIP) may affect outcomes after an allogeneic (donor-to-recipient) stem cell transplant. It may help doctors better predict which donor factors are important for patient outcomes.
Hong KongAges 18 years+ - NCT05682755RecruitingPhase 1/Phase 2
Chidamide to Prevent AML Return After Bone Marrow Transplant
This Phase 1/2 study tests whether chidamide can help prevent high-risk acute myeloid leukemia (AML) from coming back after an allogeneic bone marrow transplant (allo-HSCT). Participants must already be in complete remission and have recovered blood counts after transplant.
Chengdu, SichuanAges 18–65
Hear when a new HSCT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hsct?
- Yes. Clin2 currently lists 160 recruiting hsct studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hsct trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hsct trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.